Evaluation	B:C0220825
of	O
Pharmacokinetics	B:C0031327
,	O
and	O
Bioavailability	O
of	O
Higher	O
Doses	O
of	O
Tocotrienols	B:C0949647
in	O
Healthy	O
Fed	O
Humans	B:C0086418
.	O

Tocotrienols	B:C0949647
has	O
been	O
known	O
to	O
lower	B:C0856969
serum	I:C0856969
lipid	I:C0856969
parameters	I:C0856969
below	O
500	O
mg/d	O
,	O
while	O
increase	B:C0856968
lipid	I:C0856968
parameters	I:C0856968
at	O
higher	O
dose	O
of	O
750	O
mg/d.	O

δ-	B:C0218003
Tocotrienol	I:C0218003
has	O
a	O
novel	O
inflammatory	O
property	O
of	O
concentration	O
-	O
dependent	O
inhibition	O
and	O
activation	O
.	O

Therefore	O
,	O
inhibition	O
(	O
anti-inflammatory	O
)	O
property	O
of	O
tocotrienols	B:C0949647
at	O
low	O
doses	O
is	O
useful	O
for	O
cardiovascular	B:C0007222
disease	I:C0007222
,	O
whereas	O
,	O
activation	O
(	O
pro-inflammatory	O
)	O
property	O
using	O
high	O
dose	O
is	O
found	O
effective	O
for	O
treatments	B:C0087111
of	O
various	O
types	O
of	O
cancer	B:C0006826
.	O

We	O
have	O
recently	O
described	O
plasma	B:C0032105
bioavailability	O
of	O
125	O
mg/d	O
,	O
250	O
mg/d	O
and	O
500	O
mg/d	O
doses	O
of	O
δ-	B:C0218003
tocotrienol	I:C0218003
in	O
healthy	O
fed	O
subjects	B:C2349001
,	O
which	O
showed	O
dose	O
-	O
dependent	O
increases	B:C1708492
in	I:C1708492
area	I:C1708492
under	I:C1708492
the	I:C1708492
curve	I:C1708492
(	O
AUC	O
)	O
and	O
maximum	O
concentration	O
(	O
Cmax	O
)	O
.	O

Hence	O
,	O
in	O
the	O
current	O
study	O
,	O
higher	O
doses	O
of	O
tocotrienols	B:C0949647
have	O
used	O
to	O
analyze	O
its	O
effect	O
on	O
plasma	B:C0032105
pharmacokinetic	B:C1705911
parameters	I:C1705911
.	O

To	O
evaluate	B:C0220825
the	O
safety	O
and	O
bioavailability	O
of	O
higher	O
doses	O
(	O
750	O
mg	O
and	O
1000	O
mg	O
)	O
of	O
annatto	B:C0051928
-	O
based	O
tocotrienols	B:C0949647
in	O
healthy	O
fed	O
subjects	B:C2349001
.	O

All	O
four	O
isomers	O
(	O
α-	O
,	O
β-	O
,	O
γ-	O
,	O
δ-	O
)	O
of	O
tocols	B:C0599549
(	O
tocotrienols	B:C0949647
and	O
tocopherols	B:C0087096
)	O
present	O
in	O
the	O
plasmas	B:C0032105
of	O
subjects	B:C2349001
were	O
quantified	O
and	O
analyzed	B:C0936012
for	O
various	O
pharmacokinetic	B:C1705911
parameters	I:C1705911
.	O

An	O
open	B:C1709323
-	I:C1709323
label	I:C1709323
,	O
randomized	B:C2986910
study	I:C2986910
was	O
performed	O
to	O
analyze	O
pharmacokinetics	B:C0031327
and	O
bioavailability	O
of	O
δ-	B:C0218003
tocotrienol	I:C0218003
in	O
6	O
healthy	O
fed	O
subjects	B:C2349001
.	O

All	O
subjects	B:C2349001
(	O
3/	O
dose	O
)	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
each	O
dose	O
of	O
750	O
mg	O
or	O
1000	O
mg	O
.	O

Blood	B:C0178913
samples	I:C0178913
were	O
collected	O
at	O
0	O
,	O
1	O
,	O
2	O
,	O
4	O
,	O
6	O
,	O
8	O
h	O
intervals	O
and	O
all	O
isomers	O
of	O
α-	B:C0217873
,	O
β-	B:C0217992
,	O
γ-	B:C0206999
,	O
δ-tocotrienols	B:C0218003
,	O
and	O
tocopherols	B:C0087096
in	O
plasmas	B:C0032105
were	O
quantified	O
by	O
HPLC	B:C0008562
.	O

Oral	B:C0001563
administration	I:C0001563
of	O
750	O
and	O
1000	O
mg/d	O
of	O
tocotrienols	B:C0949647
resulted	O
in	O
dose	O
-	O
dependent	O
increases	O
in	O
plasmas	B:C0032105
(	O
ng/ml	O
)	O
AUC	O
t0-	O
t8	O
6621	O
,	O
7450	O
;	O
AUC	O
t0-∞	O
8688	O
,	O
9633	O
;	O
AUMC	O
t0-∞	O
52497	O
,	O
57199	O
;	O
MRT	O
6.04	O
,	O
5.93	O
;	O
Cmax	O
1444	O
,	O
1592	O
(	O
P<	O
0.05	O
)	O
,	O
respectively	O
,	O
of	O
δ-	B:C0218003
tocotrienol	I:C0218003
isomer	I:C0218003
.	O

Moreover	O
,	O
both	O
doses	O
also	O
resulted	O
in	O
plasmas	B:C0032105
Tmax	O
3.33	O
-	O
4	O
h	O
;	O
elimination	O
half	O
-	O
life	O
(	O
t1/2	O
h	O
)	O
2.74	O
,	O
2.68	O
;	O
time	O
of	O
clearance	O
(	O
Cl	O
-	O
T	O
,	O
l/h	O
)	O
0.086	O
,	O
0.078	O
;	O
volume	O
of	O
distribution	O
(	O
Vd/f	O
,	O
mg	O
/	O
h	O
)	O
0.34	O
,	O
0.30	O
;	O
and	O
elimination	O
rate	O
constant	O
(	O
ke	O
;	O
h(	O
-	O
1	O
)	O
)	O
0.25	O
,	O
0.17	O
,	O
respectively	O
of	O
δ-	B:C0218003
tocotrienol	I:C0218003
isomer	I:C0218003
.	O

Similar	O
results	O
of	O
these	O
parameters	B:C0449381
were	O
reported	B:C0700287
for	O
γ-	B:C0206999
tocotrienol	I:C0206999
,	O
β-	B:C0217992
tocotrienol	I:C0217992
,	O
α-	B:C0217873
tocotrienol	I:C0217873
,	O
δ-	B:C0304915
tocopherol	I:C0304915
,	O
γ-	B:C0017054
tocopherol	I:C0017054
,	O
and	O
β-	B:C0005287
tocopherol	I:C0005287
,	O
except	O
for	O
α-	B:C0969677
tocopherol	I:C0969677
.	O

This	O
study	O
has	O
described	O
pharmacokinetics	B:C0031327
using	O
higher	O
doses	O
of	O
750	O
mg/d	O
and	O
1000	O
mg/d	O
of	O
δ-tocotrienol	B:C0218003
.	O

These	O
results	O
confirmed	O
earlier	O
findings	O
that	O
Tmax	O
was	O
3	O
-	O
4	O
h	O
for	O
all	O
isomers	O
of	O
tocotrienols	B:C0949647
and	O
tocopherols	B:C0087096
except	O
for	O
α-	B:C0969677
tocopherol	I:C0969677
(	O
6	O
h	O
)	O
.	O

These	O
higher	O
doses	O
of	O
tocotrienols	B:C0949647
were	O
found	O
safe	O
in	O
humans	B:C0086418
and	O
may	O
be	O
useful	O
for	O
treatments	B:C0087111
of	O
various	O
types	O
of	O
cancer	B:C0006826
,	O
diabetes	B:C0011847
,	O
and	O
Alzheimer	B:C0002395
's	I:C0002395
disease	I:C0002395
.	O

